Dr Lazaros Andronis MSc Phd

Dr Lazaros Andronis

Institute of Applied Health Research
Lecturer in Health Economics

Contact details

Address
Health Economics Unit
IOEM Building
Institute of Applied Health Research
College of Medical and Dental Sciences
University of Birmingham
Edgbaston
Birmingham
B15 2TT
UK

Dr Lazaros Andronis is a Lecturer in Health Economics at the Health Economics Unit of the University of Birmingham. His research focuses on the use of economic and decision-analytic tools to study and inform the allocation of public resources to health care programmes and health-related research.

Dr Andronis has been involved in designing, coordinating or conducting work funded by various national programmes including the National Institute for Health and Care Excellence, the National Institute for Health Research and the Medical Research Council.

He has been the lead applicant and co-applicant in research proposals for both methodological and applied work, he has published research on top-tier disciplinary journals and he has presented his works at numerous international conferences and invited seminars. 

In addition to research, Dr Andronis delivers lectures to undergraduate Economics and postgraduate health economics students, supervises research students and reviews grant applications submitted to national and international funding organisations.

Dr Andronis is currently co-ordinating a team of health economists who provide advice on research proposals through the NIHR Research Service Design West Midlands (RDS WM) programme. 

ResearchGate: https://www.researchgate.net/profile/Lazaros_Andronis

Qualifications

Research Fellow in Health Economics

  • PhD in Health Economics (funded by a NIHR Doctoral Research Fellowship award), University of Birmingham, 2013
  • MSc in Health Economics and Health Policy (funded by a Greek State Scholarships Foundation (IKY) studentship award), University of Birmingham, 2006
  • B.A. in Health Services Management, Technological Educational Institution of Athens, Greece 2003

Biography

Dr Andronis joined the Health Economics Unit in 2006 after completing his MSc in Health Economics and Health Policy. From 2006 to 2009, Dr Andronis was involved in undertaking economic evaluations of health care technologies (DAMASK and BRUM-CHF projects), appraising the economic evidence submitted to the National Institute for Health Care Excellence (NICE) and evaluating the cost-effectiveness of public health interventions targeting cardiovascular disease and skin cancer.

In 2009, Dr Andronis was awarded a NIHR Doctoral Research Fellowship award to look into the role and value of analytic approaches as a means of guiding the allocation of public resources across research programmes. This work was presented in Dr Andronis’ thesis, which was submitted in November 2012 and was examined by Professors M. Buxton (Brunel) and W. Hollingworth (Bristol).

Upon completion of his PhD, Dr Andronis was offered a Lectureship in Health Economics, which funds his current employment at HEU.

Teaching

Dr Andronis delivers sessions on the following courses and modules

BA in Economics

  • Demand for health care: theory and empirical evidence
  • Demand for health care: the Grossman model
  • Benefit assessment in healthcare: the travel cost method
  • Benefit assessment in healthcare: stated preference methods and choice experiments

MSc in Health Economics and Health Policy

Dr Andronis delivers various lectures in the following modules of this MSc programme.

  • Introduction to Health Economics
  • Economic Evaluation in Health Care
  • Policy and Economics of Health Care Delivery
  • Statistics for Health Economics I
  • Statistics for Health Economics II
  • Modelling in Health Economics

Masters of Public Health (MPH)

  • Identifying measuring and valuing costs in economic evaluation
  • Measuring and valuing outcomes in economic evaluation

MSc in Clinical Oncology

  • Economic evaluation of health care technologies

Postgraduate supervision

Dr Andronis is currently co-supervising a doctoral project on the economics of vitamin D supplementation in the UK.

Research

Dr Andronis  is involved in the following research activities:

Current research

  • BASIL-2: Multi-centre randomised controlled trial to compare the clinical and cost-effectiveness of a ‘vein bypass first’ with a ‘best endovascular first’ revascularisation strategy for severe limb ischaemia due to infra-geniculate arterial disease.   Study funded by the National Institute of Health Research Health Technology Assessment  (NIHR HTA) programme.
  • BASIL-3. The clinical and cost effectiveness of new minimally invasive treatments for patients with critical limb ischaemia.   Study funded by the National Institute of Health Research Health Technology Assessment (NIHR HTA) programme.
  • BLUEBELLE: a feasiBiLity stUdy of complEx, simple and aBsEnt wound dressings in eLective surgery.   Funded by the NIHR Health Technology Assessment programme.

Selected past research projects:

  • Doctoral project ‘Exploring the role and value of analytic approaches in informing research funding decisions’. Funded by NIHR TCC. Examiners: Professor M. Buxton (Brunel University London), Professor W. Hollingworth (University of Bristol).
  • Economic evaluation of chemotherapy combinations for patients with hormone-refractory prostate cancer, using data from the TRAPEZE clinical trial.   Funded by the NIHR HTA  programme.   I led on and completed the economic evaluation component of this study.
  • ‘Clinical and cost-effectiveness of stem cell transplant in the management of acute leukaemia—a systematic review’. Funded by the NIHR HTA programme.   I was involved in identifying, appraising and interpreting the available economic evidence.
  • ‘Prevention of cardiovascular disease’ and ‘Providing resources to prevent skin cancer’. Programmes commissioned by the NICE Centre for Public Health Excellence (CPHE).     As a co-investigator in both projects, I collaborated with Dr Pelham Barton in carrying out the economic analyses and presenting the findings to the designated NICE CPHE panel.
  •  ‘Sensitivity analysis in economic evaluation: An audit of NICE current practice and a  review of its use and value in decision making’.   Funded by the NIHR HTA programme.   I undertook the required systematic review, appraised and synthesised the retrieved information, and contributed a number of sections in the report.
  • Appraisal of Infliximab for the treatment of (acute and sub-acute) ulcerative colitis.   Single Technology Appraisal (STA) projects (TA 163 and TA 140) commissioned by NICE.   As part of the Evidence Review Team, I appraised the available manufacturer evidence, liaised with the NICE technical lead and collaborated in undertaking additional analyses.
  • Economic evaluation of early access to MRI scan using data from the DAMASK.    Funded by the Medical Research Council.   I undertook the economic evaluation and wrote up the article reporting the results under the supervision of Professor Stirling Bryan.

Other activities

- Member of the NIHR Research Design Service West Midlands http://www.rds-wm.nihr.ac.uk/).

As part of this role, Dr Andronis co-ordinates the team of health economist RDS advisors at the University of Birmingham and engages in providing advice on the design of economic components of research projects submitted for funding to national competitions. To date, Lazaros has provided advice on proposals submitted to funding organisations including the Research Councils, the NIHR and medical charities. 

- Co-applicant in research projects submitted to national funding programmes:

  • BASIL-3. The clinical and cost effectiveness of new minimally invasive treatments for patients with critical limb ischaemia. As the lead health economist co-applicant, I designed the economic analysis component of this application and I am responsible for planning the collection of economic and quality of life data, overseeing the completion of the economic analysis and coordinating the dissemination of findings. 
  • BASIL-2: Multi-centre randomised controlled trial to compare the clinical and cost-effectiveness of revascularisation strategies for severe limb ischaemia.   As a co-applicant (lead health economist: Professor Tracy Roberts, Birmingham),      I contributed to the design of the economic analysis and I am responsible for executing the analysis plan.
  • BLUEBELLE: a feasiBiLity stUdy of complEx, simple and aBsEnt wound dressings in eLective surgery.   As a co-applicant health economist (lead health economist: Professor Joanna Coast, Bristol) I am involved in the design of various aspects of the study and I am responsible for carrying out preliminary analyses (e.g. systematic reviews to identify relevant cost information, preliminary modelling) and undertaking the planned economic evaluation.

Presenter at conferences and invited seminars

Lazaros has disseminated findings of his work to fellow researchers, NHS policy makers, practitioners, economists and research students and the public through presentations at conferences and invited seminars.

  • Andronis L.    Exploring the impact of treatment uptake on treatment recommendations and research funding decisions. School of Health and Population Sciences (HaPS) Monthly Seminar Series, University of Birmingham, 4 November 2015.
  • Andronis L.     Adjusting Value of Information for implementation: a theoretical framework.   Health Economics Research Group (HERG) External Seminar Series.      Brunel University, 5 August 2015
  • Andronis L.   Analytic methods for research prioritization: obstacles, uncertainties and the way forward. Keele University, 28 April 2014
  • Andronis L.   Is there a role for analytic approaches in setting priorities for research. Centre for Clinical Epidemiology and Evaluation Rounds, Vancouver Coastal Health Authority, University of British Columbia; Vancouver, 21 January 2012

Warwick Economics Summit 2013.  Lazaros was Invited to be be on the expert panel for Economics of Health and Health Care. Warwick University, June 2013. 

Conference presentations:

  • Andronis L.   Using analytic approaches for research priority-setting: strengths and limitations.  9th European Conference on Health Economics (ECHE); Zurich, 18-21 July 2012
  • Andronis L, Billingham L, Bryan S and Barton P.    Analytic approaches to inform cost-effective priorities for health care research.   8th World Congress in Health Economics; Toronto, 10-13 July 2011
  • Andronis L, Billingham L, Bryan S and Barton P.   Using analytic approaches to inform the allocation of cancer research resources. 8th European Conference on Health Economics      (ECHE); Helsinki, 7-10 July 2010
  • Andronis L, Billingham L, Bryan S and Barton P.   Assessing the potential role and value of analytic approaches in assisting research priority-setting. Health Economists’ Study Group; Oxford, 25-27 June 2012.
  • Andronis L, Bryan S and Barton P. Analytic approaches to inform research funding decisions:      Evidence from a systematic literature review. 10th International Conference on Health Economics, Management and Policy; Athens, 27-30 June 2011.

Reviewer of grant applications

Lazaros has reviewed manuscripts submitted for publication in numerous scientific journals, including Health Economics, European Journal of Health Economics, Value in Health, Social Science and Medicine, British Medical Journal, Health Technology Assessment and PLoS ONE. 

Lazaros has reviewed applications for programme grants and personal awards submitted to various funding programmes including the National Institute for Health Research, the Economic and Social Research Council, the Medical Research Council, the Netherlands Organisation for Health Research and Development (ZonMw)) and various medical charities.

Publications

Andronis L, Barton P.      Adjusting estimates of the expected value of information for implementation: theoretical framework and practical application. Medical Decision Making 2016, 36(3): 296

Andronis L, Barton P.      Adjusting the expected value of sample information using realistic expectations around implementation. Medical  Decision Making 2016, 36(3): 284

Andronis L, Billingham, L,  Bryan S, Barton P.   A practical application of value of information and prospective payback of research to prioritise evaluative research. Medical Decision Making 2016, 36(3): 321

Thorn J, Coast J, Andronis L.   Interpretation of the expected value of perfect information and research recommendations: a  systematic review. Medical Decision Making 2016, 36(3): 285

Duarte R, Andronis L, Lenders M, de Vos C.   Quality of life in patients with painful diabetic neuropathy following treatment with spinal cord stimulation. Quality of Life Research 2015 DOI: 10.1007/s11136-015-1211-4.  In press.

Popplewell M, Deeks J, Andronis L, Roberts T,  Bradbury A.   Bypass versus angio plasty in severe ischaemia of the leg - 2      (BASIL-2) trial: study protocol for a randomised controlled trial. Trials 2015 DOI: 10.1186/s13063-015-1114-2. In press

James N, Pirrie S, Pope A, Barton D, Andronis L,  Goranitis I et al.   Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel with strontium-89, zoledronic acid, neither, or both. JAMA Oncology 2015. 312-464-JAMA. In press

Mantopoulos T,  Mitchell P, Welton N, McManus R, Andronis  L.   Choice of statistical model for cost-effectiveness analysis and covariate adjustment: empirical application of prominent models and  assessment of their results. European Journal of Health Economics 2015. In Press. DOI: 10.1007/s10198-015-0731-8

Andronis L.   Analytic approaches for research priority-setting: issues, challenges and the way forward. Expert Review of Pharmacoeconomics and Outcomes Research 2015 Oct;15(5):745-54.

James N, Pirrie S, Pope A, Barton D, Andronis L  et al.   TRAPEZE: A randomised  controlled trial of the clinical and cost effectiveness of chemotherapy with zoledronic acid, strontium-89 or both, in men with bony metastatic castrate refractory prostate cancer.  Health Technology Assessment 2015.     In press

James N, Andronis L, Goranitis I, Pirrie S, Pope A, Barton D et al.   Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer. J  Clin Oncol 33 (suppl; abstr e16108), 2015

Brealey S, Andronis L, Dale V, Gibbon A, Gilbert F and Hendry M.   The effect of waiting times from General Practitioner referral to Magnetic Resonance Imaging or orthopaedic consultation for the knee on patient-based outcomes. British Journal of Radiology. 2012 85 (1019): e1134-e1139

Bryan S,  Dormandy E, Roberts T, Ades A, Barton P, Juarez-Garcia A, Andronis L, Karnon J and Marteau T.   Screening for sickle cell and thalassaemia in primary care: a cost-effectiveness study. British Journal of General Practice 2011; 61(591):620-627

Barton P, Andronis L, Briggs A, McPherson K and Capewell S.   Effectiveness and cost-effectiveness of cardiovascular disease prevention in whole populations: modelling study. British Medical Journal 2011 28:  343

Ashfaq K, Yahaya I , Hyde C, Andronis L, Barton P, Bayliss S et al.   Clinical effectiveness and cost-effectiveness of stem cell transplantation in the management of acute leukaemia: a systematic review. Health Technology Assessment 2010 Dec;14(54):iii-xi, 1.

Brealey S, Andronis L, Dennis L, Atwell C,  Bryan S, Coulton S et al. Participants'  preference for type of leaflet used to feed back the results of a  randomised trial: a survey. Trials 2010;11:16.

Pennant M, Takwoingi Y, Pennant L, Davenport C, Fry-Smith A, Eisinga A, Andronis L et al.   A systematic review of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence. Health Technology Assessment 2010 Oct;14(50):1-103.

Bryan S, Andronis L, Hyde C, Connock M, Fry-Smith A and Wang D.   Infliximab for the treatment of acute exacerbations of ulcerative colitis. Health Technology Assessment 2010 May;14 Suppl 1:9-15.

Hyde C, Bryan S,  Juarez-Garcia A, Andronis L and Fry-Smith A.   Infliximab for the treatment of ulcerative colitis. Health Technology Assessment 2009 Oct;13 Suppl 3:7-11.

Andronis L, Barton P and Bryan S.   Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making. Health Technology Assessment 2009   Jun;13(29):iii, ix-61.

DAMASK Trial Team (Brealey S, Andronis L,  Atwell C,  Bryan S, Collins S,  Coulton S et al.)   Effectiveness of GP access to MRI of the knee: a  randomised trial. British Journal of General Practice 2008; 58(556): e1-8

DAMASK Trial Team (Brealey S, Andronis L, Atwell C, Bryan S, Collins S, Coulton S et al.)   Cost effectiveness of magnetic resonance imaging of the knee for patients presenting in primary care. British Journal of General Practice 2008; 58(556): e10-16